A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes

source extracted confidence: high 2026-04-09
#adult #autoimmunity #dietary-supplements #double-blind-method #female

A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes

de et al., 2015 | J Endocrinol Invest | Rct

Citation

de Farias C R, Cardoso B R, ... Knobel M. A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes. J Endocrinol Invest. 2015-Oct;38(10):1065-74. doi:10.1007/s40618-015-0285-8

Abstract

PURPOSE: To analyze the impact of selenium supplementation on serum antiTPO levels and thyroid echogenicity in patients with CAT, evaluating the response in subgroups with different GPx1 genotypes. METHODS: CAT patients (n = 55) with positive antiTPO were randomized to selenomethionine (SeMet) 200 μg daily (n = 28) or placebo (n = 27) for 3 months. Assessments included GPx1 genotyping at baseline and serum levels of plasma selenium, erythrocyte GPx1 activity, antiTPO and thyroid echogenicity at baseline, and 3 and 6 months. RESULTS: In the SeMet group, the increase in plasma levels of selenium and erythrocyte GPx1 activity was similar among patients with different GPx1 genotypes. In the overall cohort, patients randomized to SeMet showed a 5 % decrease in antiTPO levels at 3 months (p = non-significant) and 20 % at 6 months (p < 0.001 versus 3 months). In contrast, patients in the placebo group did not show significant changes in antiTPO levels at any time point. Subgroup analysis showed that patients with different GPx1 genotypes presented comparable responses in antiTPO levels and echogenicity index to SeMet. CONCLUSIONS: Selenium supplementation decreased serum antiTPO levels in CAT patients, with similar response among patients with different GPx1 genotypes.

Key Findings

In the SeMet group, the increase in plasma levels of selenium and erythrocyte GPx1 activity was similar among patients with different GPx1 genotypes. In the overall cohort, patients randomized to SeMet showed a 5 % decrease in antiTPO levels at 3 months (p = non-significant) and 20 % at 6 months (p < 0.001 versus 3 months). In contrast, patients in the placebo group did not show significant changes in antiTPO levels at any time point. Subgroup analysis showed that patients with different GPx1 ge

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population cat
Sample Size 55
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Autoimmunity
  • Dietary Supplements
  • Double-Blind Method
  • Female
  • Genotype
  • Glutathione Peroxidase
  • Humans
  • Inflammation
  • Iodide Peroxidase
  • Male
  • Middle Aged
  • Selenomethionine
  • Thyroid Gland
  • Thyroiditis, Autoimmune
  • Treatment Outcome
  • Young Adult
  • Glutathione Peroxidase GPX1

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
  • Vertical: selenium-thyroid

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09